Literature DB >> 6710512

A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans.

J C Ramsey, M E Andersen.   

Abstract

A physiologically based pharmacokinetic model which describes the behavior of inhaled styrene in rats accurately predicts the behavior of inhaled styrene in humans. The model consists of a series of mass-balance differential equations which quantify the time course of styrene concentration within four tissue groups representing (1) highly perfused organs, (2) moderately perfused tissues such as muscle, (3) slowly perfused fat tissue, and (4) organs with high capacity to metabolize styrene (principally liver). The pulmonary compartment of the model incorporates uptake of styrene controlled by ventilation and perfusion rates and the blood:air partition coefficient. The metabolizing tissue group incorporates saturable Michaelis-Menten metabolism controlled by the biochemical constants Vmax and Km. With a single set of physiological and biochemical constants, the model adequately simulates styrene concentrations in blood and fat of rats exposed to 80, 200, 600, or 1200 ppm styrene (data from previously published studies). The simulated behavior of styrene is particularly sensitive to changes in the constants describing the fat tissue group, and to the maximum metabolic rate described by Vmax. The constants used to simulate the fate of styrene in rats were scaled up to represent humans. Simulated styrene concentrations in blood and exhaled air of humans are in good agreement with previously published data. Model simulations show that styrene metabolism is saturated at inhaled concentrations above approximately 200 ppm in mice, rats, and humans. At inhaled concentrations below 200 ppm, the ratio of styrene concentration in blood to inhaled air is controlled by perfusion limited metabolism. At inhaled concentrations above 200 ppm, this ratio is controlled by the blood:air partition coefficient and is not linearly related to the ratio attained at lower (nonsaturating) exposure concentrations. These results show that physiologically based pharmacokinetic models provide a rational basis with which (1) to explain the relationship between blood concentration and air concentration of an inhaled chemical, and (2) to extrapolate this relationship from experimental animals to humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6710512     DOI: 10.1016/0041-008x(84)90064-4

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  62 in total

1.  Cancer risk assessment for the inhalation of 1,3-butadiene using physiologically based pharmacokinetic modeling.

Authors:  W H Hallenbeck
Journal:  Bull Environ Contam Toxicol       Date:  1992-07       Impact factor: 2.151

2.  Evaluation of occupational exposure: comparison of biological and environmental variabilities using physiologically based toxicokinetic modeling.

Authors:  G Truchon; R Tardif; G Charest-Tardif; A de Batz; P O Droz
Journal:  Int Arch Occup Environ Health       Date:  2012-03-13       Impact factor: 3.015

3.  Sensitivity analysis for physiologically based pharmacokinetic models.

Authors:  D M Hetrick; A M Jarabek; C C Travis
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

4.  Pharmacokinetic interaction between 1,3-butadiene and styrene in Sprague-Dawley rats.

Authors:  R J Laib; M Tucholski; J G Filser; G A Csanády
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

5.  Altered pharmacokinetics of soil-adsorbed benzene administered orally in the rat.

Authors:  C Travis; J Bowers
Journal:  Bull Environ Contam Toxicol       Date:  1990-08       Impact factor: 2.151

6.  Development of appropriate equations for physiologically based pharmacokinetic modeling of permeability-limited and flow-limited transport.

Authors:  Matthew D Thompson; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-05-17       Impact factor: 2.745

7.  Variability in biological monitoring of solvent exposure. I. Development of a population physiological model.

Authors:  P O Droz; M M Wu; W G Cumberland; M Berode
Journal:  Br J Ind Med       Date:  1989-07

8.  Effect of variation of exposure to airborne chlorobenzene on internal exposure and concentrations of urinary metabolite.

Authors:  S Kumagai; I Matsunaga
Journal:  Occup Environ Med       Date:  1995-01       Impact factor: 4.402

9.  Inhalation dosimetry modeling with decamethylcyclopentasiloxane in rats and humans.

Authors:  Micaela B Reddy; Ivan D Dobrev; Debra A McNett; Joseph M Tobin; Mark J Utell; Paul E Morrow; Jeanne Y Domoradzki; Kathleen P Plotzke; Melvin E Andersen
Journal:  Toxicol Sci       Date:  2008-06-26       Impact factor: 4.849

10.  A physiologically based mathematical model for the human inhalation pharmacokinetics of 1,1,2-trichloro-1,2,2-trifluoroethane.

Authors:  T R Auton; B H Woollen
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.